Clinical trials
Efficacy and Safety clinical trials
Below are recruiting efficacy and safety clinical trials, each written for real people, not researchers. We’re tracking 2,831 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT06664021RecruitingPhase 2
Tislelizumab and S-1 for recurrent high-risk bile duct cancer
This trial tests a combination of two drugs (tislelizumab and S-1) for people whose bile duct cancer has come back after surgery and had high-risk features. The goal is to see if this treatment can help control the cancer.
Fuyang, AnhuiAges 18–75 - NCT06664125RecruitingPhase 2
New drug for high phosphorus in dialysis patients
This trial tests a new drug, JMKX003002, to lower high phosphorus levels in people with end-stage kidney disease who are on hemodialysis. If you have trouble controlling your phosphorus, this treatment might help.
Guangzhou, GuangdongAges 18 years+ - NCT06666491RecruitingPhase 3
Comparing two malaria treatments for P. vivax in people 2 and older
This study compares two medicines (tafenoquine and primaquine) taken with chloroquine to treat P. vivax malaria. It aims to see which is safer and works better in Indian participants aged 2 to 64.
AhmedabadAges 2–64 - NCT06666946Recruiting
Electroacupuncture for sepsis patients in the ICU
This study tests whether gentle electrical stimulation through thin needles placed in the lower legs (electroacupuncture) can help patients fight sepsis in the ICU. It aims to see if this treatment reduces organ damage and speeds recovery.
Wuhan, HubeiAges 18 years+ - NCT06667752Recruiting
Antibacterial wound dressing for diabetic foot ulcers
This trial tests a new antibacterial wound dressing to see if it helps heal diabetic foot ulcers safely. It may be an option if your ulcer has been there for over 4 weeks and is not severely infected.
Tallinn, HarjuAges 18 years+ - NCT06668792RecruitingPhase 2
Study of BCD-248 for returning multiple myeloma
This trial tests a new treatment called BCD-248 for people whose multiple myeloma has come back or stopped responding to at least two prior treatments. It aims to see if it is safe and effective.
KaliningradAges 18 years+ - NCT06671054RecruitingPhase 2
Testing AP1189 for newly diagnosed active rheumatoid arthritis
This study tests an oral drug called AP1189 for people just diagnosed with active rheumatoid arthritis who haven't yet taken standard arthritis medicines. You may be able to take part if your disease is very active and you're ready to try a new treatment option.
Cutler Bay, FloridaAges 18 years+ - NCT06674148RecruitingPhase 2/Phase 3
Qifangfeixian granules for connective tissue disease lung scarring
This trial tests a Chinese herbal medicine called Qifangfeixian granules for people with lung scarring (interstitial lung disease) related to connective tissue diseases (like lupus or scleroderma). It compares the medicine to a placebo to see if it helps improve breathing and lung function.
Wuhan, HubeiAges 18–80 - NCT06674265RecruitingPhase 1
Natural killer cells for advanced neuroblastoma
This trial tests a new type of immune cell called natural killer (NK) cells from healthy donors to treat neuroblastoma that has not responded to standard treatments. The goal is to see if these cells can help shrink or control the cancer.
TehranAges 2–16 - NCT06678113RecruitingPhase 1/Phase 2
Testing a new IV drug for serious fungal infections
This trial tests BSG005, a new IV medicine for patients with invasive fungal infections that haven't improved with standard treatment or can't use standard treatments due to side effects or resistance. The goal is to see if it's safe and effective.
Dehli, HaryanaAges 18–100 - NCT06681623Recruiting
Ublituximab in older adults with relapsing MS
This study is testing how safe and effective the medication ublituximab is for older adults (ages 55–80) with relapsing multiple sclerosis. It aims to see if this treatment works well for this age group.
Foxborough, MassachusettsAges 55–80 - NCT06682793RecruitingPhase 1/Phase 2
Study of A2B395 therapy for solid tumors with EGFR and HLA loss
This trial tests a new cell therapy called A2B395 for cancers that have EGFR, a protein on the cell surface, and have lost a specific marker called HLA-A*02. The therapy uses specially engineered immune cells to target and kill these cancer cells. This may help patients with colorectal, lung, head and neck, breast, kidney, or other solid tumors that are no longer responding to standard treatments.
Gilbert, ArizonaAges 18 years+ - NCT06684379RecruitingPhase 1/Phase 2
Two Doses of PRS CK STORM for Severe Viral Pneumonia
This study tests a new drug called PRS CK STORM to see if it can safely calm the body's overactive immune response (cytokine storm) in people with severe pneumonia from COVID-19, flu, or RSV who need oxygen. It aims to reduce inflammation and improve recovery.
Alcalá de Henares, MadridAges 18 years+ - NCT06689085RecruitingPhase 3
Testosterone replacement study for adolescent boys with low testosterone
This trial tests a testosterone injection (XYOSTED) to see if it's safe and effective for replacing testosterone in teenage boys who have low levels due to a known medical condition. It lasts 52 weeks, with an optional 2-year follow-up.
Los Angeles, CaliforniaAges 12–17 - NCT06689852Recruiting
Study of two treatments for nail fungus
This trial tests two different treatments for fungus that affects the fingernails or toenails. It is designed to see how well the treatments work and if they are safe.
Villeurbanne, FranceAges 18–70 - NCT06691152RecruitingPhase 1
CD19 UCAR T cells for severe lupus
This trial tests an experimental treatment called CD19 UCAR T cells for people with severe lupus that hasn't gotten better with standard medicines. It aims to see if these special immune cells can safely and effectively control the disease.
Hangzhou, ZhejiangAges 5 years+ - NCT06691555Recruiting
Long-term safety of a silicone tube eye implant
This study follows up with people who have previously received a special silicone tube implant in their eye to see how they are doing over time. It aims to check the long-term safety and how well the implant is working.
TbilisiAges 40–90 - NCT06692244Recruiting
Custom 3D-printed mesh for jawbone regrowth
This trial is testing a custom-made titanium mesh (built with a 3D printer) to help regrow bone in your jaw where teeth are missing. It may be an option if you have moderate to severe bone loss and need a strong foundation for dental implants.
Guangzhou, GuangdongAges 18–60 - NCT06693362RecruitingPhase 1
Stem cell therapy for severe viral pneumonia
This trial tests whether injecting stem cells from the womb's blood supply can help treat severe viral pneumonia. It aims to improve recovery for people who are very sick and need hospital care.
Shanghai, Shanghai MunicipalityAges 18–85 - NCT06693973RecruitingEarly Phase 1
AcNK-Sup003 cell therapy for relapsed B-cell lymphoma
This early-phase trial tests a new immune cell treatment called AcNK-Sup003 for people with B-cell non-Hodgkin's lymphoma that has come back or not responded to prior therapy. The goal is to see if it is safe and effective.
Wuhan, HubeiAges 18 years+ - NCT06695897Recruiting
Long-term real-world study of Dupilumab for eosinophilic esophagitis
This study looks at how well Dupilumab works over time in people aged 12 and older with eosinophilic esophagitis (EoE) whose symptoms are not well controlled by standard treatments. It aims to understand the medicine's effects in everyday medical practice.
Dachau, BavariaAges 12 years+ - NCT06695988Recruiting
Time-restricted eating for weight management in adults with obesity
This study tests if limiting your eating to a certain window of hours each day (time-restricted eating) is a safe and effective way to manage weight for healthy adults with obesity and a sedentary lifestyle.
Oxford, MississippiAges 19–65 - NCT06696794RecruitingPhase 3
Testing mitomycin before surgery for high-risk bladder cancer
This trial tests whether giving mitomycin directly into the bladder before surgery can help people with high-risk non-muscle-invasive bladder cancer. The goal is to see if this approach is safe and effective at preventing cancer from coming back.
Wuhan, HubeiAges 18–75 - NCT06697301RecruitingPhase 2/Phase 3
New drug with pembrolizumab for advanced melanoma
This trial tests a new drug (EIK1001) combined with the standard immunotherapy pembrolizumab (Keytruda) for people with advanced melanoma that cannot be removed by surgery or has spread. The goal is to see if adding EIK1001 is more effective than placebo plus pembrolizumab.
Chandler, ArizonaAges 18 years+
Hear when a new Efficacy and Safety trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for efficacy and safety?
- Yes. Clin2 currently lists 2,831 recruiting efficacy and safety studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a efficacy and safety trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a efficacy and safety trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.